COMP <GO>
GLUE vs SANA // GROSS PROFIT MARGIN
Monte Rosa Therapeutics Inc. (NASDAQ) VS. Sana Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: GLUE 2
— SANA 1
■ METRIC PARITY
LAST: $10.87 (+0.18%) • MKT CAP: $927.4M
gross-margins
—
LAST: $2.72 (+3.42%) • MKT CAP: $814.3M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLUE VS. SANA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GLUE | SANA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.97% | -17.78% | +14.81 | GLUE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.6 | 46.1 | -1.50 | SANA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $927.4M | $814.3M | $113.1M | GLUE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GLUE REV | SANA REV | GLUE GROSS % | SANA GROSS % | GLUE FCF | SANA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$27.5M | -$144.8M |
| FY 2024 | $0 | $0 | — | — | $38.0M | -$256.6M |
| FY 2023 | $0 | $0 | — | — | -$43.8M | -$253.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLUE // BETA —
SANA // BETA —